STAAR Surgical Free Cash Flow 2010-2023 | STAA
STAAR Surgical free cash flow from 2010 to 2023. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| STAAR Surgical Annual Free Cash Flow |
| 2023 |
-3.59 |
| 2022 |
17.61 |
| 2021 |
30.32 |
| 2020 |
12.55 |
| 2019 |
15.70 |
| 2018 |
10.52 |
| 2017 |
1.81 |
| 2016 |
-2.16 |
| 2015 |
-4.21 |
| 2014 |
-12.01 |
| 2013 |
-0.09 |
| 2012 |
0.95 |
| 2011 |
4.41 |
| 2010 |
-4.71 |
| 2009 |
0.90 |
| STAAR Surgical Quarterly Free Cash Flow |
| 2023-12-31 |
-3.59 |
| 2023-09-30 |
-32.48 |
| 2023-06-30 |
-17.32 |
| 2023-03-31 |
-8.00 |
| 2022-12-31 |
17.61 |
| 2022-09-30 |
18.66 |
| 2022-06-30 |
0.83 |
| 2022-03-31 |
-7.15 |
| 2021-12-31 |
30.32 |
| 2021-09-30 |
26.51 |
| 2021-06-30 |
7.47 |
| 2021-03-31 |
4.61 |
| 2020-12-31 |
12.55 |
| 2020-09-30 |
-4.86 |
| 2020-06-30 |
-12.40 |
| 2020-03-31 |
-10.36 |
| 2019-12-31 |
15.70 |
| 2019-09-30 |
8.83 |
| 2019-06-30 |
-0.39 |
| 2019-03-31 |
-1.47 |
| 2018-12-31 |
10.52 |
| 2018-09-30 |
8.70 |
| 2018-06-30 |
1.04 |
| 2018-03-31 |
1.57 |
| 2017-12-31 |
1.81 |
| 2017-09-30 |
0.77 |
| 2017-06-30 |
-1.99 |
| 2017-03-31 |
-0.94 |
| 2016-12-31 |
-2.16 |
| 2016-09-30 |
-1.79 |
| 2016-06-30 |
-2.46 |
| 2016-03-31 |
-3.99 |
| 2015-12-31 |
-4.21 |
| 2015-09-30 |
-1.60 |
| 2015-06-30 |
-2.10 |
| 2015-03-31 |
-2.54 |
| 2014-12-31 |
-12.01 |
| 2014-09-30 |
-6.88 |
| 2014-06-30 |
-6.27 |
| 2014-03-31 |
-4.01 |
| 2013-12-31 |
-0.09 |
| 2013-09-30 |
0.44 |
| 2013-06-30 |
-1.66 |
| 2013-03-31 |
-1.65 |
| 2012-12-31 |
0.95 |
| 2012-09-30 |
2.55 |
| 2012-06-30 |
0.40 |
| 2012-03-31 |
-0.72 |
| 2011-12-31 |
4.41 |
| 2011-09-30 |
4.71 |
| 2011-06-30 |
2.73 |
| 2011-03-31 |
0.53 |
| 2010-12-31 |
-4.71 |
| 2010-09-30 |
-4.88 |
| 2010-06-30 |
-5.30 |
| 2010-03-31 |
-1.51 |
| 2009-12-31 |
0.90 |
| 2009-09-30 |
0.02 |
| 2009-06-30 |
-0.38 |
| 2009-03-31 |
-0.57 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$2.141B |
$0.322B |
|
Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma.
|
